Company intelligence / Profile preview

Element Genomics

Durham, North Carolina, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~8
Development stage: Preclinical

Overview

Element Genomics developed proprietary technologies to interrogate and modulate genomic/epigenomic regulatory regions using CRISPR and bioinformatics. The company was acquired by UCB in 2018 to strengthen target discovery for drug development in severe disease areas. No clinical results were reported as the company operated at the discovery/preclinical stage at acquisition.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Gene editing (CRISPR)functional genomicsepigenomic modulation
Industry: Non-Drug Biotech

Partnerships

Duke University academic collaborations continued post-acquisition

Beyond the preview

Go deeper on Element Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Element Genomics.

Explore the full profile